RECORD // Company

Ligand Pharmaceuticals Inc

Formerly: LIGAND PHARMACEUTICALS

Built 2026-11-22T04:38:58Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (6)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • LIGAND PHARMACEUTICALS INC · Ca business · same registered legal name as 'LIGAND PHARMACEUTICALS INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Ligand Pharmaceuticals · Ctgov · same registered legal name as 'LIGAND PHARMACEUTICALS INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • LIGAND PHARMACEUTICALS · Epa echo · same registered legal name as 'LIGAND PHARMACEUTICALS INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • LIGAND PHARMACEUTICALS INC · Epa echo · same registered legal name as 'LIGAND PHARMACEUTICALS INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • LIGAND PHARMACEUTICALS INCORPORATED · Epa echo · same registered legal name as 'LIGAND PHARMACEUTICALS INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • LIGAND PHARMACEUTICALS, INC · Epa echo · same registered legal name as 'LIGAND PHARMACEUTICALS INC' Possible match based on name, not a shared identifier. Compare the records. Compare

5 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-10-30 · accession 0000886163-26-000060

ItemValuePeriodFormFiledAccessionReport
Revenue$78,746,0003 months ended 2026-09-3010-Q2026-10-300000886163-26-0000602026-11-22 04:38 UTCReport an error
Net income (loss)$-28,485,0003 months ended 2026-09-3010-Q2026-10-300000886163-26-0000602026-11-22 04:38 UTCReport an error
Interest expense$2,898,0003 months ended 2026-09-3010-Q2026-10-300000886163-26-0000602026-11-22 04:38 UTCReport an error
Cash and cash equivalents$55,958,000at 2026-09-3010-Q2026-10-300000886163-26-0000602026-11-22 04:38 UTCReport an error
Contract liabilities, current$621,000at 2026-09-3010-Q2026-10-300000886163-26-0000602026-11-22 04:38 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0000886163
Ticker
LGND
EIN
770160744
CUSIP
53220K504
Record ID
sx:sec:0000886163

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

33 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 04:38 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 04:38 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 04:38 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 04:38 UTCReport an error
Business address7111 FAIRWAY DRIVE, SUITE 302, PALM BEACH GARDENS, FL, 334182026-11-16SEC EDGAR company profile2026-11-22 04:38 UTCReport an error
ExchangesNasdaq, OTC, OTC, OTC, OTC2026-11-16SEC EDGAR company profile2026-11-22 04:38 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$268,087,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-22 04:38 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$124,453,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 04:38 UTCReport an error
Total assets (at 2025-12-31)$1,560,637,0002025-12-3110-K, XBRL Assets2026-11-22 04:38 UTCReport an error
Stockholders' equity (at 2025-12-31)$1,017,212,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 04:38 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$174,927,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 04:38 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$49,359,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 04:38 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$452,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 04:38 UTCReport an error
Operating lease liabilities (at 2025-12-31)$5,301,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 04:38 UTCReport an error
Form D total offering amount (D filed 2016-01-25)$85,438,4892016-01-25D2026-11-22 04:38 UTCReport an error
Form D total amount sold (D filed 2016-01-25)$85,438,4882016-01-25D2026-11-22 04:38 UTCReport an error
Form D industry groupPharmaceuticals2016-01-25D2026-11-22 04:38 UTCReport an error
Form D revenue rangeDecline to Disclose2016-01-25D2026-11-22 04:38 UTCReport an error
Form D date of first sale2016-01-082016-01-25D2026-11-22 04:38 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-10-29)On October 29, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the…2026-10-29SEC EDGAR 8-K 0000886163-26-000058 (text as filed, excerpt)2026-11-22 04:38 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-09-24)On September 24, 2026, Ligand Pharmaceuticals Incorporated (“Ligand”) issued a press release announcing its entry into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million (the “Transaction”), and certain other information regarding the Transaction. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes…2026-09-24SEC EDGAR 8-K 0000886163-26-000054 (text as filed, excerpt)2026-11-22 04:38 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-09-22)On September 22, 2026, Ligand Pharmaceuticals Incorporated (“Ligand”) issued a press release announcing that it had acquired royalty and milestone payment rights relating to Santen Pharmaceutical Co., Ltd.’s Ryjunea® from Sydnexis, Inc. for $23 million upfront (the “Transaction”), and certain other information regarding the Transaction. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934…2026-09-22SEC EDGAR 8-K 0000886163-26-000050 (text as filed, excerpt)2026-11-22 04:38 UTCReport an error
Plan (pension, plan no. 001)LIGAND PHARMACEUTICALS INC. 401(K) PLAN: 200 participants, assets $30,272,3462025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-22 04:38 UTCReport an error
Largest institutional holder #1 (13F as filed): BlackRock, Inc.$980,193,8252026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:38 UTCReport an error
Largest institutional holder #2 (13F as filed): Invesco Ltd.$379,827,6512026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:38 UTCReport an error
Largest institutional holder #3 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$359,810,3042026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:38 UTCReport an error
Largest institutional holder #4 (13F as filed): Jupiter Topco LLC$328,913,8022026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:38 UTCReport an error
Largest institutional holder #5 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$275,298,5862026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:38 UTCReport an error
Largest institutional holder #6 (13F as filed): STATE STREET CORP$261,251,8132026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:38 UTCReport an error
Largest institutional holder #7 (13F as filed): FMR LLC$241,122,1152026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:38 UTCReport an error
Largest institutional holder #8 (13F as filed): FRANKLIN RESOURCES INC$237,713,6772026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:38 UTCReport an error
Largest institutional holder #9 (13F as filed): CONGRESS ASSET MANAGEMENT CO$208,591,2682026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:38 UTCReport an error
Largest institutional holder #10 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$186,213,0202026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:38 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.